Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oxybutynin + fesoterodine + solifenacin + propiverine + trospium
- Development stage
- Unknown
- Lead developer
- Samsung Medical Center
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Oxybutynin + fesoterodine + solifenacin + propiverine + trospium refers to a group of five antimuscarinic (anticholinergic) small-molecule agents evaluated collectively in clinical research, specifically in a study (NCT01499069) sponsored by Samsung Medical Center. These agents—oxybutynin, fesoterodine, solifenacin, propiverine, and trospium—are all approved for the treatment of overactive bladder (OAB). They function by antagonizing muscarinic receptors, particularly the M3 subtype, on the detrusor muscle of the bladder to inhibit involuntary contractions and alleviate symptoms such as urgency, frequency, and urge incontinence. In the context of the Samsung Medical Center trial, these drugs were used to investigate the utility of urinary biomarkers (NGF, PGE2, and ATP) in predicting treatment response and symptom relapse.
- Brand names
- DitropanMictonorm
- Other names
- Antimuscarinic agentsAnticholinergic agents
02
Targets
CHRM2 (Muscarinic acetylcholine receptor M2)CHRM3 (M3)M1 (Muscarinic acetylcholine receptor M1)CHRM5 (M5)CHRM4 (M4)
Beyond the preview
Go deeper on oxybutynin + fesoterodine + solifenacin + propiverine + trospium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oxybutynin + fesoterodine + solifenacin + propiverine + trospium.